The AIM team will be exhibiting at the 2017 ASCB | EMBO Meeting in Philadelphia. The meeting will take place from December 2-6th, while the exhibition will be from 930am-4pm December 3-5th.
See you at:
Pennsylvania Convention Center,
1101 Arch St,
Philadelphia, PA 19107 USA.
Please email us at email@example.com if you would like to schedule a meeting.
Two Cancer Discovery papers feature a novel ex vivo immune checkpoint assay developed with AIM chips
Researchers at the Dana-Farber Cancer Institute and MIT have developed a novel ex vivo assay (above) to profile the PD-1 blockade, making it possible to interrogate the tumor immune microenvironment, develop novel therapeutic combinations, and facilitate precision immuno-oncology efforts. The assay is detailed by Jenkins et al in “Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids“, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0833
The ex vivo organotypic tumor spheroid culture system was utilised by Deng et al to show that CDK4/6 inhibition augments the response to PD-1 blockade. The effect was validated in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. The results are detailed in “CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation”, Cancer Discovery doi: 10.1158/2159-8290.CD-17-0915
Dana-Farber Cancer Institute news release (click here)
Researchers from the Dana-Farber Cancer Institute presented two posters at AACR 2017:
1. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids (abstract linked here)
2. Validation of a novel microfluidic device for screening of immune checkpoint inhibitors using 3D organotypic tumor spheroids (abstract linked here)
The researchers demonstrated that they could recapitulate sensitivity and innate resistance to PD-1 blockade ex vivo with an assay developed on AIM chips. They were able to profile the functional response to tumor PD-1 blockade ex vivo and unveil a novel strategy to advance precision immuno-oncology.